

Ref: 03/SE/LC/2023-24

Date: 25th February 2024

To,
**Head, Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Dear Sir/Madam,

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject matter, we would like to inform that Assistant Director of Drugs Control, Zone - V, Chennai - 06, has temporarily suspended the drug license of CPD Pharma Private Limited ("CPD"), a wholly owned subsidiary of the Company, for a period of seven days from 26.02.2024 to 03.03.2024, as an administrative action for the contraventions of Section 18(c) of Drugs and Cosmetics Act, 1940 read with Rule 65(9)(b) of Drugs and Cosmetics Rules, 1945 read with the condition of license, while conducting its business by CPD.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are as under:

| Sr. No. | Particulars | Details |
|---------|---|--|
| I. | Name of the authority | Assistant Director of Drugs Control, Zone - V, Chennai - 06 |
| II. | Nature and details of the action(s) taken, initiated or order(s) passed; | Temporary suspension of drug licenses of CPD Pharma Private Limited ("CPD"), a wholly subsidiary of the Company for a period of seven days from 26.02.2024 to 03.03.2024 |
| III. | Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority; | 24.02.2024 |
| IV. | Details of the violation(s)/contravention(s) committed or alleged to be committed; | Violation of section 18 (c) of Drugs and Cosmetics Act 1949 read rules 65 (9) (b) of Drugs and Cosmetic |

| | | |
|----|---|---|
| | | Rules 1945 read with conditions of license. |
| V. | Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible. | <p>There is no material impact on the financial, operations or other activities of Entero Healthcare Solutions Limited (“Entero”) being a listed entity, as the business operation of CPD was already downsized considering the operational efficiency at the region, accordingly, the supplies to external customers were discontinued after 31.01.2024.</p> <p>The revenue of CPD is 0.17% (excluding the intercompany sale) compared to total Consolidated Revenue of Entero as of half year ended September 30, 2023.</p> |

This is for your information and records.

Yours Faithfully

For Entero Healthcare Solutions Limited



Jayant Prakash
General Counsel, Company Secretary & Compliance Officer
 (Mem: F6742)